Inhibition of the CXCL12‐CXCR4 axis has resulted in increased T‐cell infiltration of PDAC tumours, and combined with checkpoint blockade, enhances pancreatic cancer therapeutic efficacy [17, 29, 30]. Here, CXCL12 is linked to pancreatic neoplasm.